ARTICLE | Targets & Mechanisms

EZH2 does it

December 9, 2010 8:00 AM UTC

Because of the link between overexpression of the histone-methylating enzyme EZH2 and cancer, many researchers were surprised by a February paper that showed mutations in the histone methyltransferase actually inactivated the enzyme in B cell lymphomas. Now, Epizyme Inc.has painted a more complete picture by showing that these EZH2 mutations also can lead to an increase in activity.1

With small molecule inhibitors of EZH2 (enhancer of zeste homolog 2) in hand, Epizyme will now put its findings to the test in mouse models of lymphoma and other EZH2-associated cancers...